CRISPR Therapeutics AG (CRSP)

62.78
NASDAQ : Health Technology
Prev Close 65.14
Day Low/High 62.50 / 65.05
52 Wk Low/High 15.55 / 73.90
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 47.17M
Market Cap 3.07B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Intellia Therapeutics Has Upside in Its DNA

Intellia Therapeutics Has Upside in Its DNA

The setup here is appealing enough to take a small, aggressive shot on the long side.

First Week Of CRSP January 2019 Options Trading

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the January 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.

CRSP Crosses Above Average Analyst Target

In recent trading, shares of CRISPR Therapeutics AG have crossed above the average analyst 12-month target price of $62.20, changing hands for $65.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FF, FSLR, GVP, IMMR, QBAK, RGNX, SSRM, VSH Downgrades: COMM, CRSP, IMKTA, LBRDA, WIT Initiations: KRP, NAOV Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as...

CRISPR Therapeutics Announces Oral Presentation Of New Data On CTX001, A CRISPR Gene-Edited Therapy For ¿-Thalassemia And Sickle Cell Disease, At The ASH Annual Meeting

CRISPR Therapeutics Announces Oral Presentation Of New Data On CTX001, A CRISPR Gene-Edited Therapy For ¿-Thalassemia And Sickle Cell Disease, At The ASH Annual Meeting

CRISPR gene-editing in hematopoietic stem cells demonstrates potential to treat ß-thalassemia and sickle cell disease through upregulation of fetal hemoglobin

CRISPR Therapeutics Submits First Clinical Trial Application For A CRISPR Gene-Edited Therapy, CTX001 In ¿-thalassemia

CRISPR Therapeutics Submits First Clinical Trial Application For A CRISPR Gene-Edited Therapy, CTX001 In ¿-thalassemia

-Phase 1/2 trial in ß-thalassemia expected to begin in 2018-

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APEI, CMP, FRPT, GLP, OPHT, SEE, TA, TIS, VRTS Downgrades: BCRH, CAFD, KO, REGN, TERP Initiations: CRSP Read on to get TheStreet Quant Ratings' detailed report:

CRISPR Therapeutics And Casebia Collaborate With CureVac On MRNA For Gene-Editing Programs

CRISPR Therapeutics And Casebia Collaborate With CureVac On MRNA For Gene-Editing Programs

CureVac's mRNA technology accessed to express Cas9 for in vivo liver-targeted therapies 

TheStreet Quant Rating: D+ (Sell)